Saturday, November 2, 2024
HomeTagsDevelopment activities

development activities

Inmagene Receives FDA’s IND Clearance for OX40 Antagonist

Inmagene Biopharmaceuticals ("Inmagene") announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics